Newsfeeds - Spark Newswire

1 minute read

Navidea’s Imaging Agent Can Distinguish Between Fibroid & Non-Fibroid Pathotype Of Rheumatoid Arthritis

Today, 4:33 AM

Navidea Biopharmaceuticals Inc (NYSE:NAVB) announced preliminary results from the ongoing NAV3-32 Phase 2B study of Tc99m Tilmanocept imaging. The trial compared…

NAVB

2 minute read

The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus’ COVID-19 Vaccine Trial Data, FDA Rejects Teva’s Schizophrenia Med, Otonomy Aces Hearing Loss Study

By Vandana Singh

Today, 4:33 AM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ALVR

4 minute read

54 Biggest Movers From Yesterday

By Lisa Levin

Today, 4:33 AM

Gainers

ACC

3 minute read

38 Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 4:33 AM

Gainers

ACC

2 minute read

23 Stocks Moving in Tuesday’s Pre-Market Session

By Lisa Levin

Today, 4:33 AM

Gainers ToughBuilt Industries, Inc. (NASDAQ: TBLT) rose 44.9% to $0.2125 in pre-market trading as the company posted a narrower FY21 loss.

ACAD

2 minute read

News

Navidea Biopharmaceuticals Receives Acceptance Letter From NYSE American

By Benzinga Newsdesk

Today, 4:33 AM

As previously disclosed, on January 28, 2022, Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and

NAVB

1 minute read

Navidea Biopharmaceutical Q4 EPS $(0.12) Misses $(0.03) Estimate

By Bill Haddad

Today, 4:33 AM

Navidea Biopharmaceutical (AMEX:NAVB) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.03) by 300 percent. This is a 9.09 percent decrease over losses of $(0.11) per share

NAVB

4 minute read

Earnings Scheduled For March 23, 2022

By Benzinga Insights

Today, 4:33 AM

Companies Reporting Before The Bell • AYRO (NASDAQ:AYRO) is expected to report earnings for its fourth quarter.

AGFY

1 minute read

Earnings

Earnings Outlook For Navidea Biopharmaceutical

By Benzinga Insights

Today, 4:33 AM

Navidea Biopharmaceutical (AMEX:NAVB) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors need to know before the announcement. Analysts estimate that Navidea Biopharmaceutical will report an earnings per share (EPS) of $-0.03.

NAVB

3 minute read

The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings

By Shanthi Rexaline

Today, 4:33 AM

Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment during the week.

APLT